Personalized treatment of lung cancer

Ravi Salgia*, Thomas Hensing, Nicholas Campbell, April K. Salama, Michael Maitland, Philip Hoffman, Victoria Villaflor, Everett E. Vokes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Lung cancer is a heterogenous group of disorders, and a difficult disease to treat. The traditional approach of surgical resection for early-stage disease, potentially followed by chemotherapy, as well chemotherapy (with or without radiation) in later stages of disease is being supplemented with a personalized approach. The personalized approach has classically been used by the oncologist based on clinical/pathological parameters such as the performance status of the patient and histology of lung cancer. As molecular mechanisms have been explored in lung cancer more recently, the personalized approach also has incorporated molecular abnormalities. In particular, EGFR, K-ras, ALK, MET, CBL, and COX2, have come to the forefront as potential biomarkers and therapeutic targets. Thus, we review the various molecular mechanisms in lung cancer and the role of novel therapeutics.

Original languageEnglish (US)
Pages (from-to)274-283
Number of pages10
JournalSeminars in Oncology
Issue number2
StatePublished - Apr 2011

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Personalized treatment of lung cancer'. Together they form a unique fingerprint.

Cite this